Chen G, Chang Z, Yuan P, Wang S, Yang Y, Liang X
RSC Adv. 2023; 13(5):3204-3209.
PMID: 36756397
PMC: 9853512.
DOI: 10.1039/d2ra07676d.
Blais J, Dean C, Lapointe G, Leeds J, Ma S, Morris L
Antimicrob Agents Chemother. 2022; 66(12):e0092122.
PMID: 36448795
PMC: 9765007.
DOI: 10.1128/aac.00921-22.
Kirk R, Ratcliffe A, Noonan G, Uosis-Martin M, Lyth D, Bardell-Cox O
RSC Med Chem. 2021; 11(12):1379-1385.
PMID: 34095845
PMC: 8126889.
DOI: 10.1039/d0md00175a.
Rong C, Shao Y, Wang Y, Zhang Y, Yu K
Environ Sci Pollut Res Int. 2018; 25(33):33196-33206.
PMID: 30255267
DOI: 10.1007/s11356-018-3278-2.
Gerasyuto A, Arnold M, Wang J, Chen G, Zhang X, Smith S
J Med Chem. 2018; 61(10):4456-4475.
PMID: 29727185
PMC: 5991783.
DOI: 10.1021/acs.jmedchem.8b00114.
Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.
Charrier C, Salisbury A, Savage V, Duffy T, Moyo E, Chaffer-Malam N
Antimicrob Agents Chemother. 2017; 61(5).
PMID: 28223393
PMC: 5404544.
DOI: 10.1128/AAC.02100-16.
Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones.
Malik M, Mustaev A, Schwanz H, Luan G, Shah N, Oppegard L
Nucleic Acids Res. 2016; 44(7):3304-16.
PMID: 26984528
PMC: 4838383.
DOI: 10.1093/nar/gkw161.
Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions.
Aldred K, Schwanz H, Li G, Williamson B, McPherson S, Turnbough Jr C
Biochemistry. 2015; 54(5):1278-86.
PMID: 25586498
PMC: 4427193.
DOI: 10.1021/bi501073v.
Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.
Marks K, Malik M, Mustaev A, Hiasa H, Drlica K, Kerns R
Bioorg Med Chem Lett. 2011; 21(15):4585-8.
PMID: 21705218
PMC: 3138821.
DOI: 10.1016/j.bmcl.2011.05.112.
Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis.
Malik M, Marks K, Mustaev A, Zhao X, Chavda K, Kerns R
Antimicrob Agents Chemother. 2011; 55(5):2335-43.
PMID: 21383100
PMC: 3088267.
DOI: 10.1128/AAC.00033-11.
Structural basis of gate-DNA breakage and resealing by type II topoisomerases.
Laponogov I, Pan X, Veselkov D, McAuley K, Fisher L, Sanderson M
PLoS One. 2010; 5(6):e11338.
PMID: 20596531
PMC: 2893164.
DOI: 10.1371/journal.pone.0011338.
Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones.
Oppegard L, Streck K, Rosen J, Schwanz H, Drlica K, Kerns R
Antimicrob Agents Chemother. 2010; 54(7):3011-4.
PMID: 20404126
PMC: 2897325.
DOI: 10.1128/AAC.00190-10.
In front of and behind the replication fork: bacterial type IIA topoisomerases.
Sissi C, Palumbo M
Cell Mol Life Sci. 2010; 67(12):2001-24.
PMID: 20165898
PMC: 11115839.
DOI: 10.1007/s00018-010-0299-5.
Efficient Synthesis of the 2-amino-6-chloro-4-cyclopropyl-7-fluoro-5-methoxy-pyrido[1,2-c]pyrimidine-1,3-dione core ring system.
Rosen J, German N, Kerns R
Tetrahedron Lett. 2010; 50(7):785-789.
PMID: 20160840
PMC: 2631556.
DOI: 10.1016/j.tetlet.2008.11.121.
Quinolones: action and resistance updated.
Drlica K, Hiasa H, Kerns R, Malik M, Mustaev A, Zhao X
Curr Top Med Chem. 2009; 9(11):981-98.
PMID: 19747119
PMC: 3182077.
DOI: 10.2174/156802609789630947.
Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV.
Pan X, Gould K, Fisher L
Antimicrob Agents Chemother. 2009; 53(9):3822-31.
PMID: 19564360
PMC: 2737838.
DOI: 10.1128/AAC.00113-09.
Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.
German N, Malik M, Rosen J, Drlica K, Kerns R
Antimicrob Agents Chemother. 2008; 52(11):3915-21.
PMID: 18765690
PMC: 2573108.
DOI: 10.1128/AAC.00330-08.
In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.
Huband M, Cohen M, Zurack M, Hanna D, Skerlos L, Sulavik M
Antimicrob Agents Chemother. 2007; 51(4):1191-201.
PMID: 17261623
PMC: 1855495.
DOI: 10.1128/AAC.01321-06.